These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 18346178

  • 1. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L, Wang LS, Liu ZQ, Zhou HH.
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [Abstract] [Full Text] [Related]

  • 2. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [Abstract] [Full Text] [Related]

  • 3. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [Abstract] [Full Text] [Related]

  • 4. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA.
    JAMA; 2009 Aug 26; 302(8):849-57. PubMed ID: 19706858
    [Abstract] [Full Text] [Related]

  • 5. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ.
    Pharmazie; 2013 Mar 26; 68(3):183-6. PubMed ID: 23556336
    [Abstract] [Full Text] [Related]

  • 6. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.
    Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T.
    Circ J; 2009 Aug 26; 73(8):1498-503. PubMed ID: 19531897
    [Abstract] [Full Text] [Related]

  • 7. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
    Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P.
    Blood; 2006 Oct 01; 108(7):2244-7. PubMed ID: 16772608
    [Abstract] [Full Text] [Related]

  • 8. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.
    Circulation; 2010 Feb 02; 121(4):512-8. PubMed ID: 20083681
    [Abstract] [Full Text] [Related]

  • 9. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
    Liu Q, Dang DS, Chen YF, Yan M, Shi GB, Zhao QC.
    Genet Test Mol Biomarkers; 2012 Nov 02; 16(11):1293-7. PubMed ID: 23046071
    [Abstract] [Full Text] [Related]

  • 10. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S, Kojuri J, Khalili A, Azarpira N.
    Biochem Pharmacol; 2012 Apr 01; 83(7):903-8. PubMed ID: 22265638
    [Abstract] [Full Text] [Related]

  • 11. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
    Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.
    J Am Coll Cardiol; 2010 Jun 01; 55(22):2427-34. PubMed ID: 20510210
    [Abstract] [Full Text] [Related]

  • 12. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
    Gajos G, Zalewski J, Nessler J, Zmudka K, Undas A, Piwowarska W.
    Kardiol Pol; 2012 Jun 01; 70(5):439-45. PubMed ID: 22623230
    [Abstract] [Full Text] [Related]

  • 13. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, Likidlilid A.
    PLoS One; 2014 Jun 01; 9(10):e110188. PubMed ID: 25329996
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
    Sridharan K, Kataria R, Tolani D, Bendkhale S, Gogtay NJ, Thatte UM.
    Indian J Pharmacol; 2016 Jun 01; 48(4):350-354. PubMed ID: 27756942
    [Abstract] [Full Text] [Related]

  • 17. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN, Sun Y, Wang L, Han RF, Xia XS, Liu J, Li X.
    Eur J Pharmacol; 2015 Jan 15; 747():29-35. PubMed ID: 25489921
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
    Furuta T, Iwaki T, Umemura K.
    Br J Clin Pharmacol; 2010 Sep 15; 70(3):383-92. PubMed ID: 20716239
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.